Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

CYP2C9 genotype vs. metabolic phenotype for individual drug dosing--a correlation analysis using flurbiprofen as probe drug.

PloS one - 1 Jan 2015

Vogl Silvia, Lutz Roman W, Schönfelder Gilbert, Lutz Werner K

Abstract excerpt

Currently, genotyping of patients for polymorphic enzymes responsible for metabolic elimination is considered a possibility to adjust drug dose levels. For a patient to profit from this procedure, the interindividual differences in drug metabolism within one genotype should be smaller than those between different genotypes. We studied a large cohort of healthy young adults (283 subjects), correlating their CYP2C9...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alleles
Share to Cyclooxygenase Inhibitors
Share to Cytochrome P-450 CYP2C9

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Gene Frequency

Share to Genetic Association Studies

Share to Pharmacogenetics

Share to Prodrugs

Share to Young Adult

Source

Open in PubMed Open full text

Identifiers

PMID: 25775139
DOI: 10.1371/journal.pone.0120403
PMCID: PMC4361569

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CYP2C9 genotype vs. metabolic phenotype for individual drug dosing--a correlation analysis using flurbiprofen as probe drug.PMID 25775139Read ↗

Differences in flurbiprofen pharmacokinetics between CYP2C9*1/*1, *1/*2, and *1/*3 genotypes.Semantic proximity Read ↗

Physiologically based pharmacokinetic (PBPK) modeling of flurbiprofen in different CYP2C9 genotypes.Semantic proximity Read ↗

Should Race-Genotype Interactions Be Considered in the Global Development of CYP2C19 Substrates? A Proposed Framework Using Physiologically Based Pharmacokinetic Modeling.Semantic proximity Read ↗

A model-based analysis of the CYP2C9 genotype effects on fluconazole inhibition using flurbiprofen, ketoprofen and tolbutamide as probe drugs.Semantic proximity Read ↗

Markers of Individual Drug Metabolism: Towards the Development of a Personalized Antidepressant Prescription.Semantic proximity Read ↗

Differential genotype dependent inhibition of CYP2C9 in humans.Semantic proximity Read ↗

Use of microdose phenotyping to individualise dosing of patients.Semantic proximity Read ↗

Evaluation of the genetic component of variability in CYP3A4 activity: a repeated drug administration method.Semantic proximity Read ↗

Cytochrome P450 2D6 phenotype and genotype in hypertensive patients on long-term therapy with metoprolol.Semantic proximity Read ↗

Pheno- or genotype for the CYP2C19 drug metabolism polymorphism: the influence of disease.Semantic proximity Read ↗

Problems and perspectives of phenotyping for drug-metabolizing enzymes in man.Semantic proximity Read ↗

Pharmacokinetics and phenotyping properties of the Basel phenotyping cocktail combination capsule in healthy male adults.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.